Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Scilex Holding Company (SCLX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/10/2025: SCLX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $354.38
1 Year Target Price $354.38
| 1 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -74.59% | Avg. Invested days 15 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/10/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 36.15M USD | Price to earnings Ratio - | 1Y Target Price 354.38 |
Price to earnings Ratio - | 1Y Target Price 354.38 | ||
Volume (30-day avg) 2 | Beta 1.14 | 52 Weeks Range 3.60 - 73.50 | Updated Date 07/11/2025 |
52 Weeks Range 3.60 - 73.50 | Updated Date 07/11/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -15.27 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -146.93% | Operating Margin (TTM) -557.51% |
Management Effectiveness
Return on Assets (TTM) -69.26% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 70867497 | Price to Sales(TTM) 0.71 |
Enterprise Value 70867497 | Price to Sales(TTM) 0.71 | ||
Enterprise Value to Revenue 1.4 | Enterprise Value to EBITDA -2.64 | Shares Outstanding 5493360 | Shares Floating 4990167 |
Shares Outstanding 5493360 | Shares Floating 4990167 | ||
Percent Insiders 21.59 | Percent Institutions 18.57 |
Upturn AI SWOT
Scilex Holding Company
Company Overview
History and Background
Scilex Holding Company is a biopharmaceutical company focused on developing and commercializing non-opioid therapies for pain management. It was founded as a subsidiary of Sorrento Therapeutics (SRNE) and later spun out. Significant milestones include FDA approvals for its lead products and subsequent commercialization efforts.
Core Business Areas
- Pain Management: Develops and commercializes non-opioid pain management products to address various types of pain, including acute and chronic pain.
Leadership and Structure
The leadership team consists of experienced executives in the pharmaceutical industry. The organizational structure is typical of a biopharmaceutical company, with departments focused on research and development, clinical trials, regulatory affairs, manufacturing, sales, and marketing.
Top Products and Market Share
Key Offerings
- ZTlido (lidocaine topical system) 1.8%: A prescription lidocaine topical system for the relief of pain associated with post-herpetic neuralgia (PHN). Scilex acquired this from Sorrento. Market share data is not readily available. Competitors include generic lidocaine patches, Lidoderm, and other topical analgesics. Revenue data is not publicly available.
- SP-102 (SEMDEXA): A non-opioid injectable corticosteroid product candidate for the treatment of lumbar radicular pain, or sciatica. It is currently under FDA review. If approved, competitors would include epidural steroid injections and other pain management interventions. Revenue data is not publicly available. Market share will depend on approval and adoption.
Market Dynamics
Industry Overview
The pain management market is large and growing, driven by an aging population, increasing prevalence of chronic conditions, and demand for non-opioid alternatives to traditional pain medications.
Positioning
Scilex Holding Company is positioned as a player focused on non-opioid pain management, offering alternatives to traditional opioid therapies. Its competitive advantage lies in its focus on innovative non-opioid solutions.
Total Addressable Market (TAM)
The global pain management market is estimated to be hundreds of billions of dollars. Scilex's TAM depends on the approval and adoption of its pipeline products, specifically SP-102. Their current positioning targets a significant portion of the non-opioid sector.
Upturn SWOT Analysis
Strengths
- Focus on non-opioid pain management
- Proprietary drug delivery technology
- Experienced management team
- FDA-approved product (ZTlido)
Weaknesses
- Limited commercial infrastructure
- Dependence on key products in development
- Financial constraints
- Heavily reliant on FDA approval of pipeline products
Opportunities
- Growing demand for non-opioid pain treatments
- Potential for strategic partnerships
- Expansion into new indications
- Acquisition of new technologies or products
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Pricing pressures
- Patent challenges
Competitors and Market Share
Key Competitors
- TEVA
- MYL
- ALNY
Competitive Landscape
Scilex faces significant competition from larger, more established pharmaceutical companies with greater resources. Its advantage lies in its focus on non-opioid pain management and novel drug delivery technologies. However, its smaller size and limited commercial infrastructure present challenges.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is tied to the launch of ZTlido and the development of SP-102.
Future Projections: Future growth is dependent on the approval and commercial success of SP-102 and other pipeline products. Analyst estimates will vary depending on market conditions and regulatory outcomes.
Recent Initiatives: Recent initiatives include focusing on the FDA review process for SP-102 and expanding the commercial reach of ZTlido.
Summary
Scilex Holding Company is a biopharmaceutical firm with a focus on non-opioid pain management. ZTlido provides some revenue, but its future relies on the success of SP-102. The company needs to successfully gain regulatory approval and then compete against giants in the pharmaceutical sector. It's financial resources are also limited, which represents an additional hurdle for the firm.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC filings
- Company press releases
- Analyst reports
- Company website
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a financial professional. Market share data are estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Scilex Holding Company
Exchange NASDAQ | Headquaters Palo Alto, CA, United States | ||
IPO Launch date 2021-03-05 | President, CEO & Director Mr. Jaisim Shah | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 111 | Website https://www.scilexholding.com |
Full time employees 111 | Website https://www.scilexholding.com | ||
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company also develops three product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel - SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4%, a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules), a novel low-dose delayed-release naltrexone hydrochloride, which has completed phase 1 trials for the treatment of fibromyalgia. It has an agreement with Oishi and Itochu to develop lidocaine tape products, including ZTlido and SP-103; and Lifecore Biomedical, LLC for clinical trial material manufacturing and development services for SEMDEXA. Scilex Holding Company is headquartered in Palo Alto, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.